Olaf Stüve
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olaf Stüve has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Bruce C. Cree
From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California
1 shared publicationClaude P. Genain
From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California
1 shared publication- Hans Christian von Büdingen
Clinical Neuroimmunology Unit, Department of Neurology, University Hospital Zürich, Zürich, Switzerland
1 shared publication James D. Bowen
From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California
1 shared publicationLawrence Steinman
From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California
1 shared publicationSawsan Yousef
From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California
1 shared publication
Latest Publications
- 1 September 2002
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 8 (5) , 290-301
Approved and Future Pharmacotherapy for Multiple Sclerosis
BACKGROUND– Pharmacotherapy for relapsing-remitting multiple sclerosis (MS) advanced with the demonstration that interferon β and glatiramer acetate improve the clinical course of this disease. Mitoxantrone is the first drug approved by the Food and Drug Administration for treatment of secondary progressive MS. Despite this progress, the agents presently available are only partially effective, are difficult to administer, and may have significant side effects. Several orally administered immunomodulatory agents are presently being evaluated for treatment of MS. One class of drugs, HMG CoA inhibitors (statins), is safe and well-tolerated and could become another mainstay of MS therapy. REVIEW SUMMARY– This article reviews the clinical evidence for approved MS therapies and discusses their mechanisms of action. Furthermore, the clinical and laboratory data suggesting a potential role for statins in MS therapy are discussed. CONCLUSIONS– Although treatment with interferon β, glatiramer acetate, and mitoxantrone, the approved therapies, provide important treatment options for patients with relapsing-remitting MS and secondary progressive MS, the potential benefits of other medications, including statins, should be explored in controlled clinical trials.
- 1 September 2002
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 8 (5) , 290-301
Approved and Future Pharmacotherapy for Multiple Sclerosis
BACKGROUND– Pharmacotherapy for relapsing-remitting multiple sclerosis (MS) advanced with the demonstration that interferon β and glatiramer acetate improve the clinical course of this disease. Mitoxantrone is the first drug approved by the Food and Drug Administration for treatment of secondary progressive MS. Despite this progress, the agents presently available are only partially effective, are difficult to administer, and may have significant side effects. Several orally administered immunomodulatory agents are presently being evaluated for treatment of MS. One class of drugs, HMG CoA inhibitors (statins), is safe and well-tolerated and could become another mainstay of MS therapy. REVIEW SUMMARY– This article reviews the clinical evidence for approved MS therapies and discusses their mechanisms of action. Furthermore, the clinical and laboratory data suggesting a potential role for statins in MS therapy are discussed. CONCLUSIONS– Although treatment with interferon β, glatiramer acetate, and mitoxantrone, the approved therapies, provide important treatment options for patients with relapsing-remitting MS and secondary progressive MS, the potential benefits of other medications, including statins, should be explored in controlled clinical trials.